Pricing Log in Create free account
Friday 6 November 2026 Export PVLA’s income statement to Excel — free account

Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.

EPS
−76.7%
Free cash flow
−136.4%

Quarter to June 2026, against a year earlier

175.88 19.03 +12.13%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.85
Sold, $m 13.47
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 2 1 — — — — — — — —
Sell 1 1 1 1 1 1 1 1 1 3 2 —
Insider Ownership 36.19%

Capital & Financial Ratios $m

Size
Market Cap 2,260.00
Revenue ttm 41.56
Net income ttm (61.70)
Free cash flow ttm (36.51)
Net debt Q (250.58)
Valuation
P/E 0.00
Forward P/E (1.34) (negative: loss-making)
Price / sales 54.15 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 10.38 (above 6: high)
Financial health
Current ratio Q 21.18 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (9.27)
Growth
Revenue growth Q −99.09% (below 0%: shrinking)
Operating income growth Q −131.41% (below 0%: shrinking)
EPS, this year −72.20% (below 0%: weak)
EPS, next year A −27.36% (below 0%: weak)
Revenue, next year A −53.67% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −20.80% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 48.1×, against a ten-year median of 3.9×; over the ten years it ranged from −1.2× in 2023 to 48.1× in 2026.
P/S against its own 10 years 99.82%
10-year low 10-year high
P/B against its own 10 years 83.87%
10-year low 10-year high
EV/Sales against its own 10 years 99.80%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 7 84 58 251
Receivables 6 2 — —
Inventory — — — —
Other — — — —
8 88 59 253
2023 2024 2025 Q'26
Payables 1 5 5 7
ST’ Debt — — — —
Other — 2 2 —
2 12 11 12

Compound Annual Growth %

10y 5y 3y
Sales 13.17% 8.03% 13.44%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (1.06%) (2.04%) 0.06%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.16 Actual −1.52

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.85 −1.03 Miss by 0.18
Q4 FY25 −0.95 −1.08 Miss by 0.13
Q1 FY26 −0.90 −1.20 Miss by 0.30
Q2 FY26 −1.16 −1.52 Miss by 0.36
Q3 FY26 −1.65 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.20) (1.52) — — —
’25 (0.74) (0.86) (1.03) (1.08) (3.71)
’24 (1.43) (2.76) (3.83) (0.94) (7.83)
’23 (14.40) 4.00 (8.80) — 2.17
’22 (5.60) (11.20) (10.40) (8.80) (36.00)
’21 (5.60) (20.00) (19.20) (10.40) (56.80)
’20 (5.60) (7.20) (20.80) (20.80) (54.40)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 2 20 20 — —
’22 11 4 5 6 26
’21 16 3 4 8 31
’20 13 11 3 2 29
’19 9 5 15 17 46
’18 4 12 8 5 29
’17 1 2 4 18 25
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (13) — — —
’25 (7) (5) (8) (5) (25)
’24 (1) (2) (3) (5) (11)
’23 (11) (13) (10) — (14)
’22 (23) (16) (9) (13) (60)
’21 (12) 30 (14) (11) (8)
’20 (15) (10) (8) (13) (46)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (13) — — —
’25 (7) (5) (8) (5) (25)
’24 (1) 1 0 (5) (11)
’23 (11) (13) (10) 0 (14)
’22 (23) (16) (9) (13) (61)
’21 (12) 30 (15) (11) (9)
’20 (17) (11) (7) (14) (49)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 25 29 46 29 31 26 — — — 42 +28.2% — — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — — 100.00 0.0 pt
EBT (23) (17) (27) (25) (37) (46) (33) 19 (17) (42) (62) +7.0%
EBT margin, % (388.22) (65.46) (93.01) (55.03) (126.41) (145.58) (128.47) 0.00 0.00 0.00 0.00 +388.2 pt
Net income (23) (18) (27) (25) (37) (46) (33) 19 (17) (42) (62) +6.9%
Per share, $
Per share, $ Revenue 11.18 46.03 43.86 73.13 43.06 38.94 27.94 0.00 0.00 0.00 0.00 n/m
Earnings (44.00) (32.00) (40.00) (44.80) (54.40) (56.80) (36.00) 2.19 (7.83) (3.71) (4.83) (24.0%)
Cash flow (27.59) 90.61 (1.61) (82.91) (67.39) (9.49) (64.64) (7.74) (4.87) (2.22) (2.54) (24.4%)
Capex (1.07) (3.55) (2.56) (3.89) (4.00) (1.18) (1.12) (0.10) 0.00 0.00 0.00 n/m
Free cash flow (28.67) 87.06 (4.17) (86.80) (71.40) (10.67) (65.76) (7.84) (4.87) (2.22) (2.54) (24.7%)
Book value 48.38 20.98 60.19 81.15 45.56 62.91 30.12 (2.19) 28.13 2.49 15.11 (28.1%)
Shares, m 1 1 1 1 1 1 1 2 2 11 12 +40.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — 0.00 0.0
P/S 10.44 13.47 4.85 3.96 4.64 7.77 3.12 0.62 — — 54.15 6.1
P/B 2.41 29.55 3.54 3.57 4.39 4.81 2.89 0.00 — — 10.38 6.4
EV/Sales 5.63 10.65 0.49 1.74 2.29 4.06 0.89 0.47 — — 48.15 3.3
EV/FCF (2.20) 5.63 (5.19) (1.46) (1.38) (14.81) (0.38) (1.46) — — (62.39) (2.7)
Cash, $m
Cash, $m Operating cash flow (14) 50 (1) (52) (46) (8) (60) (14) (11) (25) (37) +6.3%
Capex (1) (2) (2) (2) (3) (1) (1) 0 — — 4 (15.6%)
Free cash flow (15) 48 (3) (55) (49) (9) (61) (14) (11) (25) (37) +5.9%
Balance, $m
Balance, $m Working capital 24 44 87 88 54 77 37 5 76 48 241 +7.8%
Net debt (29) (73) (128) (104) (70) (118) (59) (7) (84) (58) (251) +7.9%
Shareholders’ equity 25 12 40 51 31 51 28 (4) 63 28 217 +1.2%
Returns, %
Returns, % ROA (66.07) (25.40) (21.82) (20.04) (30.26) (35.38) (26.72) 34.77 (36.40) (56.45) (37.70) +9.6 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (80.91) (96.04) (103.99) (62.00) (90.39) (111.85) (84.58) (76.96) 293.60 (92.10) (46.63) (11.2) pt
People
People Employees 52 68 116 127 123 141 144 50 14 29 — (6.3%)
Revenue/emp, $m 0.11 0.37 0.25 0.36 0.24 0.22 0.18 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2024 · fundamentals updated 26 Oct 2026

Palvella Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ADMA ADMA Biologics Inc $3.0B 16.7× 14.0× +5.12% (above 0%: growing) +46.67% (above 0%: growing) +1,709.49% (above 0%: growing) 70.81% 48.02% Compare
VCEL Vericel Corporation $2.7B 77.8× 72.9× +26.47% (above 0%: growing) +180.00% (above 0%: growing) −19.39% (below 0%: shrinking) 73.34% 14.27% Compare
PHVS Pharvaris N.V. $2.3B — (loss-making) — — n/m −17.31% (below 0%: shrinking) 0.00% 0.00% Compare
PVLA Palvella Therapeutics, Inc. $2.3B — (loss-making) — (loss-making) −99.09% (below 0%: shrinking) n/m −136.38% (below 0%: shrinking) 100.00% 0.00%
CLDX Celldex Therapeutics, Inc. $2.2B — (loss-making) — (loss-making) −96.83% (below 0%: shrinking) n/m −35.45% (below 0%: shrinking) 100.00% (366,468.18%) Compare
VERA Vera Therapeutics, Inc. $2.2B — (loss-making) — — n/m −82.47% (below 0%: shrinking) 0.00% 0.00% Compare
AUPH Aurinia Pharmaceuticals Inc $2.2B 6.8× 17.6× +13.93% (above 0%: growing) 0.00% +4.41% (above 0%: growing) 90.08% 40.74% Compare
IMNM Immunome, Inc. $2.1B — (loss-making) — (loss-making) +69.84% (above 0%: growing) n/m −26.96% (below 0%: shrinking) 100.00% 0.00% Compare
BHVN Biohaven Ltd. $2.1B — (loss-making) — (loss-making) +131.43% (above 0%: growing) n/m +26.55% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $2.2B 16.7× 17.6× +20.20% +46.67% −18.35% 72.08% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 17.20%
Wesley H. Kaupinen 7.70%
Entities affiliated with First Light Asset Management, LLC 6.20%
Entities affiliated with Biotechnology Value Fund, L.P. 6.10%
Entities affiliated with Suvretta Capital Management, LLC 5.70%
Entities affiliated with Frazier Life Sciences Public Fund, L.P. 5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Palvella Therapeutics, Inc. (PVLA) Latest News

5 Nov

Impact 4 · · GuruFocus.com
Impact 4 · · Moby
Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire

29 Oct

Impact 3 · · GlobeNewswire

28 Oct

Impact 4 · · GlobeNewswire

25 Oct

Impact 4 · · MarketBeat

24 Oct

Impact 4 · · Simply Wall St.

22 Oct

Impact 3 · · GlobeNewswire

15 Oct

Impact 4 · · GlobeNewswire

12 Oct

Impact 4 · · GlobeNewswire

28 Sep

Impact 4 ·

31 Aug

Impact 4 ·

16 Aug

Impact 4 · · MarketBeat

11 Aug

Impact 3 · · The Motley Fool transcript

8 Aug

Impact 4 ·

4 Aug

Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript

15 Jul

Impact 4 ·

29 Jun

Impact 4 ·

22 Jun

Impact 4 · · InvestorsHub
Impact 4 · · GlobeNewswire

3 Jun

Impact 4 · · GlobeNewswire

27 May

Impact 3 · · GlobeNewswire

20 May

Impact 4 · · GlobeNewswire

18 May

Impact 4 · · Simply Wall St.

15 May

Impact 4 · · GlobeNewswire

13 May

Impact 4 · · GlobeNewswire

PVLA metrics, ten years each

stockrow.com/PVLA · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com